MX363561B - Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal. - Google Patents

Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal.

Info

Publication number
MX363561B
MX363561B MX2013013388A MX2013013388A MX363561B MX 363561 B MX363561 B MX 363561B MX 2013013388 A MX2013013388 A MX 2013013388A MX 2013013388 A MX2013013388 A MX 2013013388A MX 363561 B MX363561 B MX 363561B
Authority
MX
Mexico
Prior art keywords
testosterone
low
present
gels
sexual
Prior art date
Application number
MX2013013388A
Other languages
English (en)
Spanish (es)
Other versions
MX2013013388A (es
Inventor
Kreppner Wayne
Fogarty Siobhan
Oberegger Werner
José Pierre Marie Maes Paul
Original Assignee
Trimel Biopharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimel Biopharma Srl filed Critical Trimel Biopharma Srl
Publication of MX2013013388A publication Critical patent/MX2013013388A/es
Publication of MX363561B publication Critical patent/MX363561B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013013388A 2011-05-15 2012-05-15 Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal. MX363561B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US201161486634P 2011-05-16 2011-05-16
PCT/IB2012/001127 WO2012156822A1 (en) 2011-05-15 2012-05-15 Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

Publications (2)

Publication Number Publication Date
MX2013013388A MX2013013388A (es) 2014-09-15
MX363561B true MX363561B (es) 2019-03-27

Family

ID=46579248

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2013013388A MX363561B (es) 2011-05-15 2012-05-15 Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal.
MX2020008599A MX395212B (es) 2011-05-15 2012-05-15 Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal.
MX2013013369A MX2013013369A (es) 2011-05-15 2012-05-15 Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino.
MX2019003340A MX374398B (es) 2011-05-15 2012-05-15 Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2020008599A MX395212B (es) 2011-05-15 2012-05-15 Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal.
MX2013013369A MX2013013369A (es) 2011-05-15 2012-05-15 Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino.
MX2019003340A MX374398B (es) 2011-05-15 2012-05-15 Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal.

Country Status (16)

Country Link
EP (3) EP2709588B1 (enExample)
JP (9) JP6152092B2 (enExample)
KR (10) KR20190117803A (enExample)
CN (4) CN110613679A (enExample)
AR (2) AR089553A1 (enExample)
AU (11) AU2012257490A1 (enExample)
BR (2) BR112013029336B1 (enExample)
CA (3) CA2836398C (enExample)
DK (1) DK2714006T3 (enExample)
EA (1) EA201391701A1 (enExample)
ES (1) ES2859784T3 (enExample)
IL (2) IL229400A0 (enExample)
MX (4) MX363561B (enExample)
PL (1) PL2714006T3 (enExample)
WO (2) WO2012156820A1 (enExample)
ZA (2) ZA201309264B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
CA2836398C (en) * 2011-05-15 2021-12-14 Trimel Biopharma Srl Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
US8971800B2 (en) * 2011-05-31 2015-03-03 Qualcomm Incorporated Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
JP6338658B2 (ja) * 2013-10-07 2018-06-06 アンタレス・ファーマ・インコーポレーテッド テストステロンの針補助ジェット注射を通じたヘマトクリット調節
JP2017513809A (ja) 2014-02-19 2017-06-01 アンタレス・ファーマ・インコーポレーテッド テストステロン組成物の針に補助されるジェット注射投与
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
TW201636045A (zh) * 2015-01-28 2016-10-16 波美西恩製藥有限責任公司 組成物、促進或增強受試者之局部毛髮飽滿度及厚度或毛髮生長之方法、包括該組成物之套組及裝置
US20160374800A1 (en) * 2015-06-29 2016-12-29 Changcheng You Implantable scaffolds for treatment of sinusitis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
KR20180117103A (ko) * 2016-01-07 2018-10-26 비라말 리미티드 각질층 및 혈청 중의 약물 농도를 최대로 하기 위한 경피 전달용 겔 조성물 및 그의 사용 방법
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN109069750B (zh) 2016-04-25 2021-09-07 科斯卡家族有限公司 药物输送系统
WO2017208072A2 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
EA201892595A1 (ru) 2016-06-03 2019-06-28 М Эт П Фарма Аг Назальные фармацевтические композиции с пористым наполнителем
CA3050361A1 (en) * 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
EP3641424B1 (en) 2017-06-17 2022-05-04 LG Electronics Inc. Method for registering a user equipment with a network slice in a wireless communication system and user equipment therefor
CN111615409A (zh) 2017-11-17 2020-09-01 科斯卡家族有限公司 用于流体输送歧管的系统和方法
US11234928B2 (en) * 2017-11-27 2022-02-01 Aska Pharmaceutical Co., Ltd. Powder preparation for nasal administration
PL3710012T3 (pl) 2018-02-02 2025-11-17 Acerus Biopharma Inc. Sposoby terapii testosteronem
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶
BR112021007877A2 (pt) 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
ES2948955T3 (es) 2018-11-30 2023-09-22 Viramal Ltd Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
MX2021007032A (es) * 2018-12-14 2021-10-22 Acerus Biopharma Inc Derivados activos de éster de testosterona, composiciones y usos de los mismos.
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
CN116600787A (zh) * 2020-11-19 2023-08-15 阿库西亚医疗有限责任公司 非水性凝胶组合物
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
BR9814014B1 (pt) * 1997-11-10 2014-10-07 Strakan Int Ltd Composição para aplicação tópica tendo propriedades de melhora da penetração
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
JP2005505587A (ja) * 2001-10-12 2005-02-24 シーエヌエス・インコーポレーテッド 含水性の点鼻ゲル及びその塗布装置
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
ATE534373T1 (de) * 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
DK1530965T3 (da) * 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
WO2006061155A2 (de) * 2004-12-09 2006-06-15 Bayer Healthcare Ag Stabilisierung von glucocorticoidestern mit säuren
EP1896038B1 (en) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Method and composition for testosterone transdermal delivery
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
ES2358619T3 (es) * 2006-10-04 2011-05-12 M & P PATENT AKTIENGESELLSCHAFT Sistema de administración de liberación controlada para aplicación nasal de neurotransmisores.
AU2008231781B2 (en) * 2007-03-23 2012-09-20 Besins Healthcare Luxembourg Sarl Compositions and method for treating pediatric hypogonadism
JP4825305B2 (ja) * 2007-09-20 2011-11-30 株式会社 資生堂 経皮吸収製剤
EP2949361B1 (en) * 2007-11-13 2017-03-22 Athenion AG C-19 steroids for treating cellulite
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
CA2836398C (en) * 2011-05-15 2021-12-14 Trimel Biopharma Srl Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Also Published As

Publication number Publication date
WO2012156820A9 (en) 2014-02-20
CN103796636B (zh) 2019-04-05
JP2017160204A (ja) 2017-09-14
ZA201309265B (en) 2016-01-27
CA3034552C (en) 2023-02-07
AU2019201618A1 (en) 2019-04-18
AR089553A1 (es) 2014-09-03
WO2012156822A1 (en) 2012-11-22
ES2859784T3 (es) 2021-10-04
WO2012156820A1 (en) 2012-11-22
JP2022078222A (ja) 2022-05-24
JP6594924B2 (ja) 2019-10-23
CN109481394B (zh) 2023-05-05
JP2022105175A (ja) 2022-07-12
IL229400A0 (en) 2014-01-30
EP2714006A1 (en) 2014-04-09
PL2714006T4 (pl) 2021-08-16
CN103796636A (zh) 2014-05-14
MX2013013388A (es) 2014-09-15
AU2017204182A1 (en) 2017-07-20
AU2022202402A1 (en) 2022-05-12
CA2836405C (en) 2021-09-07
EP2709588A1 (en) 2014-03-26
KR20140045400A (ko) 2014-04-16
AU2020210227A1 (en) 2020-08-20
CN103813784A (zh) 2014-05-21
JP2020079257A (ja) 2020-05-28
KR20210135003A (ko) 2021-11-11
BR112013029336B1 (pt) 2021-11-30
KR20210029849A (ko) 2021-03-16
MX2019003340A (es) 2019-07-04
MX2013013369A (es) 2014-10-17
EA201391701A1 (ru) 2014-04-30
AU2020267162A1 (en) 2020-12-03
JP2014513716A (ja) 2014-06-05
MX2020008599A (es) 2022-08-31
KR20190006194A (ko) 2019-01-17
ZA201309264B (en) 2015-09-30
JP2021001206A (ja) 2021-01-07
MX374398B (es) 2025-03-06
EP2709588B1 (en) 2021-08-25
AU2012257492A1 (en) 2013-12-19
AU2024216312A1 (en) 2024-10-24
KR102568894B1 (ko) 2023-08-21
CN110613679A (zh) 2019-12-27
KR20230041081A (ko) 2023-03-23
KR20140033408A (ko) 2014-03-18
CA2836398A1 (en) 2012-11-22
AU2020267162B2 (en) 2022-06-09
JP2014515038A (ja) 2014-06-26
AU2017203470A1 (en) 2017-06-22
KR20190117803A (ko) 2019-10-16
AU2019203400A1 (en) 2019-08-01
EP3977982A1 (en) 2022-04-06
JP6152092B2 (ja) 2017-06-28
KR102088038B1 (ko) 2020-03-13
KR20200028503A (ko) 2020-03-16
JP7017254B2 (ja) 2022-02-08
KR20240162608A (ko) 2024-11-15
PL2714006T3 (pl) 2021-08-16
JP2020073469A (ja) 2020-05-14
DK2714006T3 (da) 2021-03-15
IL229401A0 (en) 2014-01-30
BR112013029332A2 (pt) 2021-06-01
MX395212B (es) 2025-03-21
AR086409A1 (es) 2013-12-11
JP2018199701A (ja) 2018-12-20
CA2836405A1 (en) 2012-11-22
KR20200118228A (ko) 2020-10-14
BR112013029336A2 (pt) 2020-08-11
EP2714006B1 (en) 2020-12-09
AU2019203067A1 (en) 2019-05-23
CA2836398C (en) 2021-12-14
CN109481394A (zh) 2019-03-19
CA3034552A1 (en) 2012-11-22
AU2012257490A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
MX363561B (es) Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal.
MX2016005574A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
BR112015020804A2 (pt) dispositivo fototerapeutico, método e uso
MX2019012197A (es) Tratamiento de trastornos del ritmo circadiano.
CO6450651A2 (es) Terapia complementaria contra el cancer
MX2019006218A (es) Tratamiento de trastornos del ritmo circadiano.
MX2017012982A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
EA201300558A1 (ru) Соединения и способы для купирования боли
MX2021000954A (es) Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales.
BR112017023170A2 (pt) dispositivo de banho medicinal e seu uso
CY1124812T1 (el) Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου
BR112015028613A2 (pt) análogos de uréia com ligações por pontes substituída como moduladores de sirtuína
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
MX2015005038A (es) Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
BR112016002580A2 (pt) composição para tratamento antienvelhecimento de pele
EA201690571A1 (ru) Улучшенное портативное массажное устройство расслабляющей терапии для головы
CO2025009577A2 (es) Formulaciones líquidas de melatonina
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
UA113183C2 (xx) Спосіб лікування адикції
MX2021004656A (es) Variabilidad reductora entre pacientes de concentraciones plasmaticas de levodopa.
HK1196261A (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
EA201600229A1 (ru) Бис(5-амино-1,4-диоксо-1,2,3,4-тетрагидрофталазин-2-ил)цинк, способ его получения, фармацевтическая композиция на его основе, лечебные средства на его основе, способ лечения кожных заболеваний и способ лечения гастрита
RU2013154077A (ru) Способ биологической стрессовой психотерапии (биостресспсихотерапии)
TWD181342S (zh) 美容用按摩器